|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2011-5-3
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
The current treatment options for systemic-onset juvenile idiopathic arthritis (JIA) are methotrexate, steroids, and biologic agents. This study was undertaken to evaluate the safety of the orally active histone deacetylase inhibitor givinostat (ITF2357) and its ability to affect the disease.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1529-0131
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 by the American College of Rheumatology.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
63
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1452-8
|
|
pubmed:meshHeading |
pubmed-meshheading:21538322-Adolescent,
pubmed-meshheading:21538322-Antirheumatic Agents,
pubmed-meshheading:21538322-Arthritis, Juvenile Rheumatoid,
pubmed-meshheading:21538322-Child,
pubmed-meshheading:21538322-Female,
pubmed-meshheading:21538322-Histone Deacetylase Inhibitors,
pubmed-meshheading:21538322-Humans,
pubmed-meshheading:21538322-Hydroxamic Acids,
pubmed-meshheading:21538322-Intention to Treat Analysis,
pubmed-meshheading:21538322-Male,
pubmed-meshheading:21538322-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis.
|
|
pubmed:affiliation |
University Clinic Center, Nis, Serbia. vojinovic.jelena@gmail.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
